Phase 1 study of efatutazone, a novel oral peroxisome proliferator-activated receptor gamma agonist, in combination with FOLFIRI as second-line therapy in patients with metastatic colorectal cancer

详细信息    查看全文

• 作者：Yoshito Komatsu (1)
  Takayuki Yoshino (2)
  Kentaro Yamazaki (3)
  Satoshi Yuki (4)
  Nozomu Machida (3)
  Takahide Sasaki (1) (2)
  Ichinosuke Hyodo (5)
  Yutaka Yachi (6)
  Hiroshi Onuma (6)
  Atsushi Ohtsu (7)
  
• 关键词：Efatutazone ; Peroxisome proliferator ; activated receptor gamma ; FOLFIRI ; Colorectal cancer
• 刊名：Investigational New Drugs
• 出版年：2014
• 出版时间：June 2014
• 年：2014
• 卷：32
• 期：3
• 页码：473-480
• 全文大小：
• 参考文献：1. Nemenoff RA, Weiser-Evans M, Winn RA (2008) Activation and molecular targets of peroxisome proliferator-activated receptor-gamma ligands in lung cancer. PPAR Res 2008:156875 CrossRef
  2. Ondrey F (2009) Peroxisome proliferator-activated receptor gamma pathway targeting in carcinogenesis: implications for chemoprevention. Clin Cancer Res 15:2鈥? CrossRef
  3. Burgermeister E, Seger R (2008) PPARgamma and MEK interactions in cancer. PPAR Res 2008:309469 CrossRef
  4. Zou B, Qiao L, Wong BC (2009) Current understanding of the role of PPAR纬 in gastrointestinal cancers. PPAR Res 2009:816957 CrossRef
  5. Skelhorne-Gross G, Nicol CJ (2012) The key to unlocking the chemotherapeutic potential of PPARgamma ligands: having the right combination. PPAR Res 2012:946943 CrossRef
  6. Girnun GD, Naseri E, Vafai SB, Qu L, Szwaya JD, Bronson R, Alberta JA, Spiegelman BM (2007) Synergy between PPARgamma ligands and platinum-based drugs in cancer. Cancer Cell 11:395鈥?06 CrossRef
  7. Tikoo K, Kumar P, Gupta J (2009) Rosiglitazone synergizes anticancer activity of cisplatin and reduces its nephrotoxicity in 7, 12-dimethyl benz{a}anthracene (DMBA) induced breast cancer rats. BMC Cancer 9:107 CrossRef
  8. Chen L, Bush CR, Necela BM, Su W, Yanagisawa M, Anastasiadis PZ, Fields AP, Thompson EA (2006) RS5444, a novel PPARgamma agonist, regulates aspects of the differentiated phenotype in nontransformed intestinal epithelial cells. Mol Cell Endocrinol 251:17鈥?2 CrossRef
  9. Copland JA, Marlow LA, Kurakata S, Fujiwara K, Wong AK, Kreinest PA, Williams SF, Haugen BR, Klopper JP, Smallridge RC (2006) Novel high-affinity PPARgamma agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIP1. Oncogene 25:2304鈥?317 CrossRef
  10. Shimazaki N, Togashi N, Hanai M, Isoyama T, Wada K, Fujita T, Fujiwara K, Kurakata S (2008) Anti-tumour activity of CS-7017, a selective peroxisome proliferator-activated receptor gamma agonist of thiazolidinedione class, in human tumour xenografts and a syngeneic tumour implant model. Eur J Cancer 44:1734鈥?743 CrossRef
  11. Nakajima TE, Yamada Y, Hamano T, Furuta K, Matsuda T, Fujita S (2010) Adipocytokines as new promising markers of colorectal tumors: adiponectin for colorectal adenoma, and resistin and visfatin for colorectal cancer. Cancer Sci 101:1286鈥?291 CrossRef
  12. Pishvaian MJ, Marshall JL, Wagner AJ, Hwang JJ, Malik S, Cotarla I, Deeken JF, He AR, Daniel H, Halim AB, Zahir H, Copigneaux C, Liu K, Beckman RA, Demetri GD (2012) A phase 1 study of efatutazone, an oral peroxisome proliferator-activated receptor gamma agonist, administered to patients with advanced malignancies. Cancer 118:5403鈥?413 CrossRef
  13. Tournigand C, Andr茅 T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C, de Gramont A (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22:229鈥?37 CrossRef
  14. Muro K, Boku N, Shimada Y, Tsuji A, Sameshima S, Baba H, Satoh T, Denda T, Ina K, Nishina T, Yamaguchi K, Takiuchi H, Esaki T, Tokunaga S, Kuwano H, Komatsu Y, Watanabe M, Hyodo I, Morita S, Sugihara K (2010) Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomized phase 2/3 non-inferiority study (FIRIS study). Lancet Oncol 11:853鈥?60 CrossRef
  15. Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Kishida K, Nagaretani H, Matsuda M, Komuro R, Ouchi N, Kuriyama H, Hotta K, Nakamura T, Shimomura I, Matsuzawa Y (2001) PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 50:2094鈥?099 CrossRef
  
• 作者单位：Yoshito Komatsu (1)
  Takayuki Yoshino (2)
  Kentaro Yamazaki (3)
  Satoshi Yuki (4)
  Nozomu Machida (3)
  Takahide Sasaki (1) (2)
  Ichinosuke Hyodo (5)
  Yutaka Yachi (6)
  Hiroshi Onuma (6)
  Atsushi Ohtsu (7)
  
  1. Hokkaido University Hospital Cancer Center, Kita 14 Nishi 5, Kita-ku, Sapporo, Hokkaido, 060-8648, Japan
  2. Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan
  3. Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan
  4. Department of Gastroenterology and Hepatology, Hokkaido University Hospital, Sapporo, Japan
  5. Division of Gastroenterology, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Ibaraki, Japan
  6. Clinical Developmental Department II, Daiichi Sankyo Co., Ltd., Tokyo, Japan
  7. Exploratory Oncology Research & Clinical Trial Center, National Cancer Center Hospital East, Kashiwa, Japan
  
• ISSN：1573-0646

文摘